Potential mechanisms by which statins modulate the development of acute lung injury

Intensive Care Medicine: Annual Update 2007

Volumn , Issue , 2007, Pages 276-288

  Craig, T ^a   O'Kane, C ^a   McAuley, D ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892023100     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-49518-7_25     Document Type: Chapter

References (50)

1. Ware LB, Matthay MA (2000) The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349
2. Rubenfeld GD (2005) Incidence and outcomes in acute lung injury. N Engl J Med 363: 1685-1693
3. The Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342:1301-1308
4. The National Heart Lung and Blood Institute Acute Respiratory Distress Network (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564-2575
5. Hager DN, Krishnan JA, Hayden JL, Brower RG (2005) Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. Am J Respir Crit Care Med 172:1241-1245
6. Perkins G, McAuley D, Thickett D, Gao F (2006) The b-Agonist Lung Injury Trial (BALTI) A randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 173:281-287
7. The Long term Intervention with Pravastatin in Ischemic Disease (LIPID) study group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary artery disease and a broad range of cholesterol levels. N Engl J Med 339:1349-1357
8. Steinberg KP, Milberg JA, Martin TR, Maunder RJ, Cockrill BA, Hudson LD (1994) Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome Am J Respir Crit Care Med 150:113-122
9. Frank J, Wray C, McAuley D, Schwendener R, Matthay M (2006) Alveolar macrophages contribute to epithelial barrier dysfunction in ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 291:L1191-1198
10. Meduri GU, Headley S, Kohler G, et al (1995) Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107:1062-1073
11. O'Kane CM, Frank JA, McAuley DF (2004) Matrix metalloproteases; a potential role in the pathogenesis of the acute respiratory distress syndrome. In: Vincent JL (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Heidelberg, pp 287-300
12. Warner RL, Beltran L, Younkin EM, et al (2001) Role of stromelysin 1 and gelatinase B in experimental acute lung injury. Am J Respir Cell Mol Biol 24:537-544
13. Pugin J, Verghese G, Widmer MC, Matthay MA (1999) The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit Care Med 27:304-312
14. Fligiel S, Standiford T, Fligiel H, et al (2006) Matrix metalloproteinases and matrix metallo-proteinase inhibitors in acute lung injury. Hum Pathol 37:422-430
15. McAuley D, Frank J, Fang X, Matthay M (2004) Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med 32:1470-1476
16. Perkins G, McAuley D, Gao F, Thickett D (2004) Intravenous salbutamol reduced alveolar-capillary permeability and extra-vascular lung water in ARDS. Thorax 59 (Suppl II):T1 (abst)
17. Dudek SM, Garcia JG (2001) Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 91:1487-1500
18. Weitz-Schmidt G WK, Brinkmann V, et al (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692
19. Dichtl W DJ, Frick M, Alber HF, et al (2003) HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arteri-oscler Thromb Vase Biol 23:58-63
20. Sen-Banerjee S, Mir S, Lin Z, et al (2005) Kruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial Cells. Circulation 112:720-726
21. Martin G, Duez H, Blanquart C, et al (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-I. J Clin Invest 107:1423-1432
22. Senokuchi T, Matsumura T, Sakai M, et al (2005) Statins suppress oxidized low density lipo-protein-induced macrophage proliferation by inactivation of the small g protein-p38 MAPK pathway. J Biol Chem 280:6627-6633
23. Jacobson JR, Barnard JW, Grigoryev DN, et al (2005) Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288:L1026-1032
24. Pirat A, Zeyneloglu P, Aldemir D, et al (2006) Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg 102:225-232
25. Naidu BV, Woolley SM, Farivar AS, Thomas R, Fraga C, Mulligan MS (2003) Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg 126:482-489
26. Kaneider NC, Reinisch CM, Dunzendorfer S, Meierhofer C, Djanani A, Wiedermann CJ (2001) Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 158:23-33
27. Weber C, Erl W, Weber KS, Weber PC (1997) HMG-CoA reductase inhibitors decrease CDllb expression and CD1 lb-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 30:1212-1217
28. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100:230-235
29. Diomede L, Albani D, Sottocorno M, et al (2001) In vivo Anti-Inflammatory Effect of Statins Is Mediated by Nonsterol Mevalonate Products. Arterioscler Thromb Vase Biol 21:1327-1332
30. Rezaie-Majd A, Maca T, Bucek R, et al (2002) Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemia patients. Arterioscler Thromb Vase Biol 22:1194-1199
31. Steiner S, Speidl WS, Pleiner J, et al (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111:1841-1846
32. Li JJ, Wang Y, Nie SP, Zhang CY, et al (2007) Reduction of C-reactive protein by a single 80 mg of simvastatin in patients with unstable angina. Clin Chim Acta 376:163-167
33. Nagashima H, Aoka Y, Sakomura Y, et al (2002) A 3-hydroxy-3- mefhylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vase Surg 36:158-163
34. Aikawa M, Rabkin E, Sugiyama S, et al (2001) An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103:276-283
35. Koh K, Ahn J, Jin D, et al (2004) Comparative effects of statin and fibrate on nitric oxide bio-activity and matrix metalloproteinase in hyperlipidemia. Int J Cardiol 97:239-244
36. Wassmann S, Laufs U, Miiller K, et al (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vase Biol 22:300-305
37. Laufs U, La Fata V, Liao J (1997) Inhibition of 3-Hydroxy-3- methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272:31725-31729
38. Jacobson JR, Dudek SM, Konstantin G, et al (2004) Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 30:662-670
39. Kario K, Matsuo T, Hoshide S (1999) Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients. Blood Coagul Fibrinolysis 10:269-276
40. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA (2003) Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 285:L20-28
41. Bourcier T, Libby P (2000) Expression by human vascular smooth muscle and endothelial cells HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1. arterioscler. Thromb Vase Biol 20:556-562
42. Ware LB, Matthay MA (2001) Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 163:1376-1383
43. Hayden JM, Swartfiguer J, Szelinger S, et al (2005) Lysophosphatidylcholine stimulation of alveolar epithelial cell interleukin-8 production and neutrophil chemotaxis is inhibited by statin treatment. Proc Am Thorac Soc 2:A72 (abst)
44. Merx MW, Liehn EA, Janssens U, et al (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:2560-2565
45. Almog Y, Shefer A, Novack V, et al (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880-885
46. Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352-1357
47. Kruger P FK, Cook D, Jones M, Nimmo G (2006) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 32:75-79
48. Hackam DG MM, Li P, Redelmeier DA (2006) Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367:413-418
49. British Medical Association and Royal Pharmaceutical Society of Great Britain (2006) British National Formulary. Pharmaceutical Press, London
50. de Lemos JA, Blazing MA, Wiviott SD, et al (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes JAMA 292:1307-1316